These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8540726

  • 1. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
    Dhople AM, Ibanez MA.
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2116-9. PubMed ID: 8540726
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
    Dhople AM, Namba K.
    J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
    [Abstract] [Full Text] [Related]

  • 3. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM, Ibanez MA.
    J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM, Dimova V.
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
    Dhople AM.
    Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
    [Abstract] [Full Text] [Related]

  • 9. [Tympanostomy tube otorrhea: microbiological epidemiology, pathogen susceptibility to local antibiotics and bactericidal power of the rifamycin-olfloxacin combination].
    François M, Mariani-Kurkdjian P, Doit C, Benzekri P, Bingen E, Macé JG.
    Ann Otolaryngol Chir Cervicofac; 2001 Oct; 118(5):278-82. PubMed ID: 11845035
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM.
    Indian J Lepr; 1997 Oct; 69(4):377-84. PubMed ID: 9474513
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    Sato K, Tomioka H, Akaki T, Kawahara S.
    Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
    Visalli MA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
    Gidoh M.
    Nihon Hansenbyo Gakkai Zasshi; 2007 Feb; 76(1):11-7. PubMed ID: 17315747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.